VIRGINIA BEACH, Va.--(BUSINESS WIRE)--DOMA Technologies, Livanta, and Advanta Government Services announced today they have rebranded to form Commence, a healthcare technology company applying a data-driven, human-centered approach to improving care for beneficiaries, veterans, providers, and other stakeholders it serves. The rebrand follows last year's announcement of their acquisition and merger by Pleasant Land. “The name Commence signifies that we are embarking on a journey toward better he.

Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI , May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.

DOMA Perpetual Believes Pacira's Stock Is Undervalued, Presenting an Opportunity to Execute the Largest Buyback in the Company's History MIAMI , April 21, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC (collectively with its affiliates, "DOMA Perpetual" or "We") is a fundamentals-based, value-oriented asset management firm which beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ:  PCRX ) ("Pacira" or the "Company"). Following constructive engagement with Pacira, DOMA Perpetual believes the Company's new capital allocation announcementi represents the Board's firm commitment to enhancing shareholder value.

-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company's 2025 Annual Meeting of Stockholders.

Pacira's Stock is Down 76% Over the Last Decade, While the Board and Management Have Enriched Themselves at a Cost of Half a Billion Dollars, Roughly 50% of the Current Market Cap Under CEO and Board Member Frank Lee, the Stock Price Has Declined 33%; He is Pushing for Higher Compensation Packages for Management While Burdening Shareholders with New Risks; DOMA Believes His Views on Capital Allocation Are Misaligned With Shareholder Interest and He Has No Track Record of Creating Shareholder Value Change to the Board's Composition is Critical to Accelerate Shareholder Return and to Correct a Decade of Corporate Abuse and Lack of Stock Price Returns DOMA's Three Highly Qualified Nominees Possess Vast Experience in Strategic Capital Allocation, Risk Management, Healthcare Banking and Intellectual Property Law and Litigation MIAMI , March 14, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC ("DOMA Perpetual") is a fundamentals-based, value-oriented investor that, together with the other participants in its solicitation (collectively "DOMA" or "we"), beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences (NASDAQ: PCRX) ("Pacira" or the "Company").i DOMA today announced its nomination of three highly skilled director candidates to Pacira BioSciences Board of Directors (the "Board"): Joseph Kromholz, Philip Pucciarelli and Eric de Armas. DOMA believes electing these nominees is critical to address the Board's lack of financial sophistication and legal expertise and to correct its value-destroying capital allocation strategy.

Believes the Board Must Immediately Execute a Tender Offer for 30% of the Company Lays Out Action Plan to Restore Investor Confidence, Including an additional 10% Share Buyback in 2025 Announces Intent to Fight for Shareholders Should InMode Not Take Appropriate Action MIAMI , Jan. 15, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode") today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to accelerate and increase its stock repurchase.

Expresses Conviction in Pacira's IP and Belief that Shares are Significantly Undervalued Urges Pacira to Immediately Commence Stock Tender Offer with Cash on Hand MIAMI , Dec. 11, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC (together with its affiliates, "DOMA"), which beneficially owns approximately 4.14% of the outstanding shares of Common Stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company"), today announced that it intends to nominate four highly-qualified, independent director candidates at the Company's 2025 annual meeting of stockholders, and stated that it has hired Olshan Frome Wolosky LLP as counsel to represent it in its dealings with the Company. DOMA further stated that it believes strongly in the value of the Company's intellectual property and that the Company's stock is grossly undervalued and urged the Company to immediately commence a stock tender offer for 10 million shares using its substantial cash on hand, and then execute its already-approved $150 million buyback program using the Company's healthy and growing free cash flow.

WASHINGTON--(BUSINESS WIRE)-- #acquisition--Pleasant Land announces strategic acquisition of Livanta and DOMA Technologies to develop innovative healthcare technology platform for government.

SAN FRANCISCO--(BUSINESS WIRE)--Doma Closes Previously Announced Go Private Transaction.

Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient. Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders MIAMI , Sept.